CLIQ Digital AG

  • WKN: A0HHJR
  • ISIN: DE000A0HHJR3
  • Land: Deutschland

Nachricht vom 17.09.2021 | 10:30

Cliq Digital AG: CLIQ Digital raises forecast for gross revenue and EBITDA for the financial year 2021

Cliq Digital AG / Key word(s): Change in Forecast
Cliq Digital AG: CLIQ Digital raises forecast for gross revenue and EBITDA for the financial year 2021

17-Sep-2021 / 10:30 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


CLIQ Digital AG (ISIN: DE000A0HHJR3) raises gross revenue and EBITDA forecast for the financial year 2021.

After a very strong first half of the financial year 2021 and based on the continuing development and dynamic market environment at least until the end of the year, CLIQ expects to generate gross revenue of c.€145 million (previously: at least €140 million), representing a 36% growth compared to 2020.

The EBITDA is expected to raise to approx. €26 million (previously: c.€22 million) representing a 60% growth compared to the previous year.

All other estimates for 2021 remain unchanged.


Information and Explanation of the Issuer to this News:

Quarterly results for Q3/2021 are published on 2 November 2021.

Contact
CLIQ Digital AG
Sebastian McCoskrie
Head of Investor Relations
Grünstr. 8
40212 Düsseldorf
Germany

+49 151 52043659
s.mccoskrie@cliqdigital.com


17-Sep-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Vonovia SE: Vorstandsmitglieder von Vonovia werden ihre Bezugsrechte ausüben

30. November 2021, 16:02

Aktueller Webcast

HelloFresh SE

Capital Markets Day

08. Dezember 2021

Aktuelle Research-Studie

clearvise AG

Original-Research: clearvise AG (von First Berlin Equity Research GmbH): Buy

30. November 2021